Grail tumbles after cancer‑detection test fails in large study

Shares of cancer test maker Grail GRAL.O fall 52% to $49 premarket

Co says its test for early cancer detection failed in large study

Says main result of trial was not statistically significant but favorable trend was observed over time

GRAL says it already sells the test called Galleri and has applied for FDA approval

The Galleri trial is run with England's National Health Service and uses blood test aiming to detect cancers early by spotting DNA shed by tumors into bloodstream, GRAL says

Stock up ~68% in 2025